ACELYRIN INC (SLRN) Stock Price, Quote, News and Overview
NASDAQ:SLRN - Nasdaq - US00445A1007 - Common Stock - Currency: USD
SLRN Quote, Performance and Key Statistics
2.27
+0.04 (+1.79%)
The current stock price of SLRN is 2.27 USD. In the past month the price decreased by -2.99%. In the past year, price decreased by -45.04%.
SLRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.88 | 324.86B | ||
| AMGN | AMGEN INC | 13.11 | 146.33B | ||
| GILD | GILEAD SCIENCES INC | 13.9 | 133.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.3 | 63.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.58B | ||
| ARGX | ARGENX SE - ADR | 99.97 | 35.83B | ||
| ONC | BEIGENE LTD-ADR | 5.99 | 25.97B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.70B | ||
| NTRA | NATERA INC | N/A | 20.82B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.23B | ||
| BIIB | BIOGEN INC | 7.97 | 18.46B |
Related stock screener links
About SLRN
Company Profile
ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 83 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Company Info
ACELYRIN INC
4149 Liberty Canyon Rd.
Agoura Hills CALIFORNIA US
Employees: 93
Phone: 18054564393
ACELYRIN INC / SLRN FAQ
What is the stock price of ACELYRIN INC today?
The current stock price of SLRN is 2.27 USD. The price increased by 1.79% in the last trading session.
What is the ticker symbol for ACELYRIN INC stock?
The exchange symbol of ACELYRIN INC is SLRN and it is listed on the Nasdaq exchange.
On which exchange is SLRN stock listed?
SLRN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACELYRIN INC stock?
8 analysts have analysed SLRN and the average price target is 8.16 USD. This implies a price increase of 259.47% is expected in the next year compared to the current price of 2.27. Check the ACELYRIN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACELYRIN INC worth?
ACELYRIN INC (SLRN) has a market capitalization of 229.07M USD. This makes SLRN a Micro Cap stock.
How many employees does ACELYRIN INC have?
ACELYRIN INC (SLRN) currently has 93 employees.
What are the support and resistance levels for ACELYRIN INC (SLRN) stock?
ACELYRIN INC (SLRN) has a support level at 2.24 and a resistance level at 2.38. Check the full technical report for a detailed analysis of SLRN support and resistance levels.
Should I buy ACELYRIN INC (SLRN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLRN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLRN, evaluating the profitability, health, valuation and growth aspects
- ACELYRIN INC (SLRN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACELYRIN INC (SLRN) Sales and EPS estimates to see what analysts future expectations are.
- ACELYRIN INC (SLRN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACELYRIN INC (SLRN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACELYRIN INC (SLRN) Stock Chart to make your own analysis
- ACELYRIN INC (SLRN) Latest news and press-releases to stay up to date.
Does ACELYRIN INC (SLRN) stock pay dividends?
SLRN does not pay a dividend.
When does ACELYRIN INC (SLRN) report earnings?
ACELYRIN INC (SLRN) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of ACELYRIN INC (SLRN)?
ACELYRIN INC (SLRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.99).
What is the Short Interest ratio of ACELYRIN INC (SLRN) stock?
The outstanding short interest for ACELYRIN INC (SLRN) is 4.83% of its float. Check the ownership tab for more information on the SLRN short interest.
SLRN Technical Analysis
SLRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLRN. While SLRN has a great health rating, there are worries on its profitability.
SLRN Financial Highlights
Over the last trailing twelve months SLRN reported a non-GAAP Earnings per Share(EPS) of -2.99. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.54% | ||
| ROE | -54.16% | ||
| Debt/Equity | 0 |
SLRN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SLRN. The Buy consensus is the average rating of analysts ratings from 8 analysts.